Abbott’s coronavirus RNA test can ID NOW – but maybe not definitively.
Antigen tests are faster and cheaper than viral RNA assays, but are notably less accurate.
Robust specificity data mark Roche’s serological test out as a major competitor.
Covid-19 could mean Medtronic loses out to Abbott, its rival in the mitral valve space.
Thrive is in some ways ahead of the competition with the first-ever screening trial of a liquid biopsy, but the test’s sensitivity leaves something to be desired.
With the prevalence of coronavirus infection running at about 5%, test manufacturers and regulators alike will have to guard against false positives.
Diagnostics prove defensive for Abbott, as the company jumps the FDA’s gun with its third coronavirus test.
Cellex wins the race to get the FDA’s buy-in for a blood test to pinpoint immunity.
Sales of implants are set to fall sharply as non-urgent procedures are deferred.